<DOC>
	<DOCNO>NCT00855920</DOCNO>
	<brief_summary>This purpose clinical research determine efficacy safety experimental drug call rilonacept subject acute gout attack . Subjects participate study 30 day . Rilonacept alone compare indomethacin alone combination rilonacept plus indomethacin treat acute gout flare .</brief_summary>
	<brief_title>Study Utilizing Rilonacept Gout Exacerbations</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>1 . Male female 18 70 year age 2 . Previously meet preliminary criterion ARA classification acute arthritis primary gout 3 . Presenting acute attack ( flare ) gout within 48 hour pain onset pain least moderate severity 4 . Must least 1 03 scale swell tenderness assessment gouty index joint 5 . Current presentation acute gout flare 3 joint less 1 . Treatment NSAIDs opiate within 48 hour prior baseline assessment . Treatment longacting NSAIDs within 1 month prior baseline visit . Treatment naproxen , meloxicam , nabumetone , celecoxib indomethacin SR within 5 day prior baseline visit . 2 . Treatment oral analgesic within 6 hour baseline assessment . Treatment topical analgesic within 12 hour baseline assessment 3 . History NSAID intolerance 4 . Subjects history chronic , gouty arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Metabolism , Inborn Errors</keyword>
	<keyword>Allopurinol</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Rheumatic Diseases</keyword>
	<keyword>Metabolic disorder</keyword>
	<keyword>Purine-Pyrimidine Metabolism , Inborn Errors</keyword>
	<keyword>Gout</keyword>
	<keyword>Flare</keyword>
</DOC>